Cruz Cobalt Corp.

Cruz Cobalt Corp. se concentre sur l'acquisition et le développement de projets Cobalt de haute qualité dans des juridictions minières politiquement stables, respectueuses de l'environnement et éthiques, essentielles pour la croissance rapide des batteries rechargeables et des secteurs de l'énergie renouvelable.

French

XPhyto Therapeutics Corp.

XPhyto Therapeutics Corp. (“XPhyto”) is a diversified bioscience company with strategic assets and investments in the field of rapid pathogen screening systems and next generation drug delivery, as well as medical cannabis opportunities focused on emerging European markets.

French

XPhyto Therapeutics Corp.

XPhyto Therapeutics Corp. (“XPhyto”) is a diversified bioscience company with strategic assets and investments in the field of rapid pathogen screening systems and next generation drug delivery, as well as medical cannabis opportunities focused on emerging European markets.

English

Cruz Cobalt Corp.

Cruz Cobalt Corp is focused on acquiring and developing high-grade Cobalt projects in politically stable, environmentally responsible and ethical mining jurisdictions, essential for the rapidly growing rechargeable battery and renewable energy sectors.

English

Revive Therapeutics Ltd.

Revive Therapeutics Ltd. is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.  Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza strains including COVID-19.

French

Revive Therapeutics Ltd.

Revive Therapeutics Ltd. is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.  Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza strains including COVID-19.

English